Folgen
David Bikard
David Bikard
Institut Pasteur
Bestätigte E-Mail-Adresse bei pasteur.fr - Startseite
Titel
Zitiert von
Zitiert von
Jahr
RNA-guided editing of bacterial genomes using CRISPR-Cas systems
W Jiang, D Bikard, D Cox, F Zhang, LA Marraffini
Nature biotechnology 31 (3), 233-239, 2013
32542013
Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system
D Bikard, W Jiang, P Samai, A Hochschild, F Zhang, LA Marraffini
Nucleic acids research 41 (15), 7429-7437, 2013
14712013
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
D Bikard, CW Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ...
Nature biotechnology 32 (11), 1146-1150, 2014
10772014
Cas9 specifies functional viral targets during CRISPR–Cas adaptation
R Heler, P Samai, JW Modell, C Weiner, GW Goldberg, D Bikard, ...
Nature 519 (7542), 199-202, 2015
5852015
PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data
JR Garneau, F Depardieu, LC Fortier, D Bikard, M Monot
Scientific reports 7 (1), 8292, 2017
5562017
CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection
D Bikard, A Hatoum-Aslan, D Mucida, LA Marraffini
Cell host & microbe 12 (2), 177-186, 2012
4772012
Conjugative DNA transfer induces the bacterial SOS response and promotes antibiotic resistance development through integron activation
Z Baharoglu, D Bikard, D Mazel
PLoS genetics 6 (10), e1001165, 2010
3492010
Divergent evolution of duplicate genes leads to genetic incompatibilities within A. thaliana
D Bikard, D Patel, C Le Metté, V Giorgi, C Camilleri, MJ Bennett, O Loudet
Science 323 (5914), 623-626, 2009
3322009
Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting
GW Goldberg, W Jiang, D Bikard, LA Marraffini
Nature 514 (7524), 633-637, 2014
3162014
Consequences of Cas9 cleavage in the chromosome of Escherichia coli
L Cui, D Bikard
Nucleic acids research 44 (9), 4243-4251, 2016
3102016
Crispr-cas component systems, methods and compositions for sequence manipulation
F Zhang, L Cong, DBT Cox, P Hsu, LIN Shuailiang, RAN Fei, RJ Platt, ...
US Patent App. 14/105,035, 2014
3042014
A CRISPRi screen in E. coli reveals sequence-specific toxicity of dCas9
L Cui, A Vigouroux, F Rousset, H Varet, V Khanna, D Bikard
Nature communications 9 (1), 1912, 2018
2772018
Folded DNA in action: hairpin formation and biological functions in prokaryotes
D Bikard, C Loot, Z Baharoglu, D Mazel
Microbiology and Molecular Biology Reviews 74 (4), 570-588, 2010
2432010
Crispr-cas component systems, methods and compositions for sequence manipulation
F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang
US Patent App. 14/497,627, 2015
2422015
CRISPR-Cas component systems, methods and compositions for sequence manipulation
F Zhang, DO BIKARD, L Cong, DBT Cox, P Hsu, W Jiang, LIN Shauiliang, ...
2352015
Genome-wide CRISPR-dCas9 screens in E. coli identify essential genes and phage host factors
F Rousset, L Cui, E Siouve, C Becavin, F Depardieu, D Bikard
PLoS genetics 14 (11), e1007749, 2018
2252018
Phages and their satellites encode hotspots of antiviral systems
F Rousset, F Depardieu, S Miele, J Dowding, AL Laval, E Lieberman, ...
Cell host & microbe 30 (5), 740-753. e5, 2022
2232022
Generating functional protein variants with variational autoencoders
A Hawkins-Hooker, F Depardieu, S Baur, G Couairon, A Chen, D Bikard
PLoS computational biology 17 (2), e1008736, 2021
2142021
Innate and adaptive immunity in bacteria: mechanisms of programmed genetic variation to fight bacteriophages
D Bikard, LA Marraffini
Current opinion in immunology 24 (1), 15-20, 2012
1612012
Using CRISPR-Cas systems as antimicrobials
D Bikard, R Barrangou
Current opinion in Microbiology 37, 155-160, 2017
1602017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20